Head-to-head research summaries.
When you're trying to decide which compound the literature actually supports better for your research question — these pages compare mechanism, published trial outcomes, and where the science diverges, with primary citations.
- Retatrutide vs Tirzepatide — research differences
Retatrutide is a triple agonist (GLP-1 + GIP + glucagon); tirzepatide is a dual agonist (GLP-1 + GIP). What the research literature shows on the difference, and how it shapes what each compound is being investigated for.
- BPC-157 vs TB-500 — research differences and combined-use literature
BPC-157 and TB-500 (thymosin beta-4 fragment) are the two most-studied research peptides in tissue-repair literature. Their mechanisms differ — what the research shows, and why they're often paired in protocol papers.
- GHK-Cu vs generic "copper peptides" — what's actually in the bottle
Most products marketed as "copper peptides" contain GHK-Cu specifically — but not all. The research literature on GHK-Cu is far ahead of any other copper-peptide complex.
- Semaglutide vs Tirzepatide — GLP-1 vs GLP-1+GIP research
Semaglutide is a single-agonist (GLP-1); tirzepatide is a dual agonist (GLP-1 + GIP). The research literature shows tirzepatide produces larger metabolic effects on most endpoints, attributable to the GIP arm.
- Cagrilintide vs Semaglutide — amylin vs GLP-1 research
Cagrilintide is a long-acting amylin analogue; semaglutide is a GLP-1 agonist. They target different receptor systems, and the research literature on combined CagriSema therapy is the headline story.
- MOTS-c vs SS-31 — mitochondrial peptides compared
MOTS-c and SS-31 (elamipretide) are the two most-studied research peptides in mitochondrial-function literature. They act differently — what the studies show.
- NAD+ vs NMN — research differences in mitochondrial precursor literature
NAD+ and NMN both target the cellular NAD+ pool. Which precursor the literature favours, and what the bioavailability and route-of-administration data shows.
- Tesamorelin vs CJC-1295 — GHRH analogues compared
Tesamorelin is FDA-approved; CJC-1295 is research-grade with longer half-life. The mechanisms, half-lives, and where the literature favours each.
- Retatrutide vs Cagrilintide — different mechanisms, similar weight-loss research
Retatrutide is a triple agonist (GLP-1 + GIP + glucagon); cagrilintide is an amylin analogue. They produce comparable weight-loss magnitudes via completely different mechanisms.
- Ipamorelin vs Sermorelin — GHS vs GHRH research
Ipamorelin is a GH secretagogue (ghrelin receptor); sermorelin is a GHRH analogue. They activate complementary pathways — what the research literature shows on each.
- Sermorelin vs CJC-1295 — same parent, different half-life
Sermorelin and CJC-1295 are both modified GHRH(1-29) analogues. The key difference is half-life — minutes vs days — and what that means for research-protocol design.
- Ipamorelin vs MK-677 — injectable vs oral GH secretagogues
Both target the GHS receptor. Ipamorelin is short-acting and injectable; MK-677 (ibutamoren) is oral with a 24-hour half-life. The literature on the difference is meaningful.
- BPC-157 acetate vs arginate — salt forms compared
BPC-157 is sold as either the acetate or arginate salt. The arginate form has improved stability across pH variations; acetate is the historical default.
- Liraglutide vs Semaglutide — daily vs weekly GLP-1 research
Liraglutide (Saxenda, Victoza) is daily; semaglutide (Ozempic, Wegovy) is weekly. The research literature shows semaglutide produces larger metabolic effects with better adherence.
- Methylene blue alone vs MB + NAD+ — mitochondrial research stacks
Methylene blue and NAD+ both target mitochondrial function via different mechanisms. The research literature on combination protocols.
- GHK-Cu injectable vs topical — what the research literature shows
GHK-Cu research splits between injectable (subcutaneous) and topical (cosmetic / wound-healing) routes. Different penetration, different research applications.